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Abstract
Background: Pro-survival Bcl-2 family members can promote cancer development and contribute to treatment
resistance. Head and neck squamous cell carcinoma (HNSCC) is frequently characterized by overexpression of
anti-apoptotic Bcl-2 family members. Increased levels of these anti-apoptotic proteins have been associated
with radio- and chemoresistance and poor clinical outcome. Inhibition of anti-apoptotic Bcl-2 family members
therefore represents an appealing strategy to overcome resistance to anti-cancer therapies. The aim of this
study was to evaluate combined effects of radiation and the pan-Bcl-2 inhibitor AT-101 in HNSCC in vitro. In
addition, we determined human plasma levels of AT-101 obtained from a phase I/II trial, and compared these
with the effective in vitro concentrations to substantiate therapeutic opportunities.
Methods: We examined the effect of AT-101, radiation and the combination on apoptosis induction and clonogenic
survival in two HNSCC cell lines that express the target proteins. Apoptosis was assessed by bis-benzimide staining to
detect morphological nuclear changes and/or by propidium iodide staining and flow-cytometry analysis to quantify
sub-diploid apoptotic nuclei. The type of interaction between AT-101 and radiation was evaluated by calculating the
Combination Index (CI) and by performing isobolographic analysis. For the pharmacokinetic analysis, plasma AT-101
levels were measured by HPLC in blood samples collected from patients enrolled in our clinical phase I/II study. These
patients with locally advanced HNSCC were treated with standard cisplatin-based chemoradiotherapy and received
dose-escalating oral AT-101 in a 2-weeks daily schedule every 3 weeks.
Results: In vitro results showed that AT-101 enhances radiation-induced apoptosis with CI’s below 1.0, indicating
synergy. This effect was sequence-dependent. Clonogenic survival assays demonstrated a radiosensitizing effect with a
DEF37 of 1.3 at sub-apoptotic concentrations of AT-101. Pharmacokinetic analysis of patient blood samples taken
between 30 min and 24 h after intake of AT-101 showed a dose-dependent increase in plasma concentration with
peak levels up to 300–700 ng/ml between 1.5 and 2.5 h after intake.
Conclusion: AT-101 is a competent enhancer of radiation-induced apoptosis in HNSCC in vitro. In addition, in vitro
radiosensitization was observed at clinically attainable plasma levels. These finding support further evaluation of the
combination of AT-101 with radiation in Bcl-2-overexpressing tumors.
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Background
The current standard treatment for advanced head
and neck squamous cell cancer (HNSCC) is concur-
rent platinum-based chemoradiotherapy [1]. Despite
encouraging results, treatment is still associated with
significant toxicity and too many locoregional recurrences
[2]. Besides dose-escalation strategies, molecular targeted
drugs represent a new and promising approach to further
improve treatment results [3]. HNSCC is frequently char-
acterized by high expression levels of Bcl-2 family mem-
bers, in particular anti-apoptotic Bcl-2 and Bcl-xL, which
has been associated with radio- and chemoresistance and
poor clinical outcome [4–8].
Bcl-2 family proteins are key regulators of apoptotic
pathways [9]. The family consists of the pro-apoptotic
Bcl-2 Homology 3 (BH3) domain-only proteins, effector
proteins Bax, Bak, and the pro-survival proteins Bcl-2,
Bcl-xL, Bcl-w, Bfl-1, Mcl-1 and Bcl-B. Bax and Bak,
upon their activation, induce mitochondrial membrane
permeabilization by forming large homomultimeric pores.
The activity of Bax and Bak is counteracted by the pro-
survival Bcl-2 proteins that prevent their homomultimeri-
zation. In response to apoptotic stimuli, BH3-only pro-
teins (Bid, Bim, Bad, Puma and Noxa) activate Bax and
Bak by direct interaction, by releasing activated Bax and
Bak from their pro-survival counterparts, or more indir-
ectly, by liberating other BH3-only proteins from pro-
survival Bcl-2 proteins, allowing these to activate Bax and
Bak. BH3-mimetics represent a novel class of selective
anti-cancer drugs that mimic the function of BH3-only
proteins to induce tumor cell kill, and an appealing strat-
egy to overcome resistance to anti-cancer therapies [10].
Gossypol was one of the first natural BH3-mimetics
and has been identified as a potent inhibitor of Bcl-xL
and Bcl-2 [11]. It is a polyphenolic dialdehyde derived
from natural cottonseed and was originally applied as an
anti-fertility agent [12]. Gossypol induces apoptosis in
tumor cells with high levels of Bcl-xL and/or Bcl-2 ex-
pression, while leaving normal cells with low expression
(such as fibroblasts and keratinocytes) relatively un-
affected [13, 14]. Racemic (±)-gossypol consists of 2 en-
antiomers: (+)-gossypol and (-)-gossypol. (-)-Gossypol,
also indicated as and from here on denoted AT-101,
binds with high affinity to Bcl-xL, Bcl-2 and Mcl-1, and
is more potent in inducing apoptosis compared to
(+)-gossypol [11, 13, 15, 16].
Modulation of apoptosis is a promising strategy to im-
prove radiation-induced tumor cell kill [3]. We demon-
strated in a previous study in leukemic cell lines that the
combination of radiation and AT-101 induced more
apoptosis than the summation of their separate effects
[16]. This combined effect was additive to synergistic,
consistent with results generated in other tumor cell
models [17, 18].
Clinical trials have demonstrated that AT-101 is well tol-
erated as a single agent [19–21] and in combination with
other conventional therapies, including docetaxel/prednis-
one and cisplatin/etoposide [22, 23]. In our current phase
I/II clinical study, we evaluate the feasibility, toxicity pro-
file and pharmacokinetics of AT-101 in combination with
cisplatin-based chemoradiotherapy in patients with locally
advanced HNSCC.
The present report describes results from in vitro stud-
ies on the interaction between AT-101 and radiation in
HNSCC cell lines, and from the pharmacokinetic analyses
of our clinical phase I/II study in HNSCC patients. We
showed that AT-101 is a potent enhancer of radiation-
induced apoptosis in vitro, and importantly, that in vitro




(-)-Gossypol/AT-101 was provided by Ascenta Therapeutics,
Inc. (San Diego, CA, USA). Stock solutions were prepared in
dimethylsulfoxide to a concentration of 20 mM and stored
at 4 °C. Prior to use an aliquot was diluted in Dulbecco’s
modified Eagle’s medium (DMEM; GIBCO-BRL, Paisley,
Scotland). Polyclonal rabbit anti-Bcl-xL and anti-Mcl-1 was
from Cell Signaling Technology, and monoclonal mouse
anti-Bcl-2 from Sigma-Aldrich.
Cell culture
Two human head and neck squamous cell carcinoma
(HNSCC) cell lines were used in this study. UM-SCC-
11B was derived from a primary tumor of the larynx.
This cell line was established at the laboratory of Dr.
T.E. Carey (University of Michigan, Ann Arbor, MI,
USA). VU-SCC-OE, an oral cavity carcinoma cell line,
was a kind gift of Professor R.H. Brakenhoff (Department
of Otolaryngology/Head and Neck Surgery, VU University
Medical Center, Amsterdam, The Netherlands). These cell
lines were grown in DMEM supplemented with 8 % heat-
inactivated fetal calf serum, glutamine (2 mM), penicillin
(50 U/ml) and streptomycin (50 μg/ml) in a humidified in-
cubator with 5 % CO2 at 37 °C. These cell lines were
tested to exclude Mycoplasma infection.
Western blotting
To assess expression levels of Bcl-2, Bcl-xL, and Mcl-1,
Western blot analysis was performed as previously described
[16]. Equivalent protein loading was confirmed by total pro-
tein staining with 0.4 % Ponceau Red in 3 % trichloroacetic
acid for 5 min. In these experiments blots were probed with
Bcl-xL polyclonal antibody (1:1000) in 5 % nonfat dry milk,
Bcl-2 monoclonal antibody (1:000) in 1 % nonfat dry
milk, and Mcl-1 polyclonal antibody (1:1000) in 5 %
BSA. After secondary horseradish peroxidase-conjugated
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antibody incubation, proteins were detected using the ECL
detection system (GE Healthcare, Buckinghamshire, UK)
and exposed to Amersham Hyperfilm MP (GE Healthcare,
Buckinghamshire, UK).
Irradiation procedure
For in vitro irradiation experiments, cells were ex-
posed to gamma rays from a Gammacell® 40 Exactor
(Best Theratronics Ltd. Ottawa, Ontario, Canada) at a
dose rate of approximately 1 Gy/min. In control con-
ditions, cells were sham-irradiated.
Apoptosis assay
Apoptosis was assessed by staining with bis-benzimide
to detect morphological nuclear changes or by propi-
dium iodide staining and FACScan analysis to determine
the percentage of subdiploid apoptotic nuclei as de-
scribed earlier [16].
Clonogenic survival assay
Cells were irradiated, 20 h later plated and allowed to at-
tach for 6 h. AT-101 was then added and maintained in
the culture medium for another 72 h. AT-101 was subse-
quently washed away and fresh medium was added.
Cells were cultured for at least 14 days to allow colony
formation. Colonies were fixed and stained with 0.2 %
crystal violet/2.5 % glutaraldehyde. Colonies consisting
of 50 cells or more were counted. The surviving fraction
of cells was calculated by normalizing plating efficiency
values of the treated samples to the untreated controls.
Dose enhancement factor was determined at surviving
fraction of 0.37 (DEF37).
Statistical analysis
To characterize the interaction between ionizing radi-
ation and AT-101 the Combination Index (CI) was
calculated and isobolographic analysis was performed.
The CI was calculated according to the classic isobo-
logram equation described by Chou and Talalay [24]:
CI = (D)1/(Dx)1 + (D)2/(Dx)2
In this equation, (Dx)1 and (Dx)2 represent the doses
Dx of compounds 1 and 2 alone required to produce an
effect, and (D)1 and (D)2 represent isoeffective doses D
when compounds 1 and 2 are given simultaneously. The
Combination Index can either indicate additivity (CI = 1),
synergism (CI < 1) or antagonism (CI > 1). For isobolo-
graphic analysis, dose response curves of both AT-101 and
radiation were generated using Graph Pad Prism 4.0 soft-
ware. From each combination effect classic isobolograms
were constructed [25]. A combination point below or above
the envelope of additivity indicated a synergistic or antag-
onistic interaction between both stimuli, respectively.
Clinical phase I/II trial
Patient selection criteria
Patients were eligible when aged 18 years or older, with
stage III or IV, M0 histologically proven locally advanced
inoperable HNSCC of the oral cavity, oropharynx or hy-
popharynx, and performance status WHO 0–2. Patients
had no prior radiotherapy to the head and neck region
or prior cisplatin-based chemotherapeutic treatment. Pa-
tients were required to have adequate hematologic, liver
and renal function, and no uncontrolled arrhythmia. The
study was approved by the Ethical Review Committee of
The Netherlands Cancer Institute. Signed written in-
formed consent was required before study entry.
Study design
Patients received standard cisplatin-based chemoradio-
therapy (consisting of 70 Gy delivered in 35 fractions
over 7 weeks, concurrently with 3-weekly 100 mg/m2
cisplatin i.v.) combined with dose-escalating oral admin-
istration of AT-101 in a 2-weeks daily schedule every
3 weeks. The starting dose of AT-101 was 10 mg daily
and dose-escalation was in steps of 10 mg. Based on
previously reported pharmacokinetic parameters [26]
AT-101 was daily administered 2 h prior to fractionated
radiation. The primary endpoint of this study was toler-
ability of AT-101 administration in combination with
standard chemoradiotherapy. Secondary endpoints in-
cluded pharmacokinetics of AT-101.
Pharmacokinetic evaluation
Blood samples were collected at 30 min after AT-101 in-
take, and after 1, 2, 3, 4, 5, 6, 7, 8 and 24 h. The 3 ml
whole blood samples were collected in EDTA tubes and
mixed with 0.3 ml 0.2 M freshly prepared reduced
gluthatione, and centrifuged at 4 °C. After centrifu-
gation the plasma was transferred in equal portions
into 2 tubes containing 75 μl 25 mM acetonitrile
maleic anhydride that was air-dried. The samples
were stored at −80 °C until analysis. Plasma concen-
trations of AT-101 were determined by an HPLC-UV
method derived from literature [26] which was opti-
mized and validated. In short, an Agilent Zorbax
Stable Bond C-18 column (150 x 4.6 mm I.D.
3.5 μm particle size) was used. Mobile phase con-
sisted of 20 % 10 mM KH2PO4 : 80 % acetonitrile,
at the flow rate of 1.0 ml/min. AT-101 was detected
with a UV detector at 236 nm. Quantification was
performed using calibration standards. An acceler-
ated stability study was conducted at four different
temperatures (37 °C, 21 °C, 4 °C and −20 °C) and
led to a prediction of approximately 88.7 % of the
original AT-101 concentration in the patient samples
up to four years of storage at −80 °C.
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Results
AT-101 target proteins are expressed in HNSCC cell lines
Western blot analysis demonstrated that HNSCC cell
lines, specifically UM-SCC-11B, UM-SCC-14C, UM-SCC-
22A and VU-SCC-OE, all expressed the anti-apoptotic
proteins Bcl-xL, Bcl-2, and Mcl-1 (Fig. 1). Further investi-
gation revealed that all four cell lines showed responsive-
ness to both radiation and AT-101 with ED50 values
between 6 Gy and 16 Gy for radiation and ED50 values be-
tween 16 μM and 44 μM for AT-101. We continued our
experiments with UM-SCC-11B and VU-SCC-OE since
Bcl-xL and Bcl-2, the major targets of AT-101, were most
prominently expressed in UM-SCC-11B and VU-SCC-OE,
respectively. Mcl-1, a less predominant target of AT-101,
was expressed at lower amounts.
Radiation and AT-101 induce apoptosis in HNSCC cell
lines
Radiation and AT-101 induced apoptosis in a time- and
dose-dependent fashion (Fig. 2). UM-SCC-11B showed a
steep dose–response curve up to 25 μM AT-101; in this
cell line no further increase in apoptosis was detected up
to 100 μM AT-101. Inserts show the time-dependency
for both treatments. Apoptosis, induced by radiation and
AT-101, as well as the combinations, results of which
are described in the next paragraph, could be inhibited
by pan-caspase inhibitor Z-VAD-FMK. In addition, we
verified apoptosis induction by determining caspase 3
activation by methods described in [27] data not shown).
Combined effects of radiation and AT-101 are synergistic
As demonstrated in Fig. 3a and b, the combination of ra-
diation and AT-101 leads to a more than additive apop-
totic effect. Isobolographic analysis, a statistical method
to determine the type of interaction, shows a synergistic
increase of apoptosis in VU-SCC-OE (Fig. 3c). Isobolo-
graphic analysis could not be performed in UM-SCC-
11B, because the maximum levels of apoptosis induced
by either radiation or AT-101 in these cells did not ex-
ceed the apoptosis levels after combined treatment, im-
plicating synergy. Consistent with this observation the
CI’s are below 1.0, in these cells.
Synergistic interactions between radiation and AT-101 are
sequence dependent
Previously, it has been shown in other cell systems that
the synergistic interaction between radiation and AT-101
can be sequence-dependent [16, 18]. We therefore also
assessed this phenomenon in our HNSCC cell lines by
comparing AT-101 administration 24 h before, during
and 24 h after irradiation. Only when radiation preceded
AT-101 treatment, this synergistic increase of apoptosis
was found (Fig. 4).
Clonogenic survival assays
To determine the impact of AT-101 on long-term sur-
vival after radiation, we performed clonogenic survival
assays. At concentrations of AT-101 below 2 μM (i.e. in
the range where no significant apoptosis induction was
found; Fig. 2) no significant decrease in clonogenic sur-
vival was observed (data not shown). Fig. 5 shows that
AT-101 at a final concentration of 1 μM reduced clono-
genic survival after radiation (DEF37 = 1.3), consistent
with a radiosensitizing effect of AT-101.
Pharmacokinetic analysis in patient samples
In an ongoing phase I/II trial, patient blood samples were
collected between 30 min and 24 h after oral intake of AT-
101. Two dose levels could be analyzed; 10 mg (n = 13) and
20 mg (n = 1). Fig. 6 shows the pharmacokinetic profiles
with a dose-dependent increase in plasma concentration,
peaking between 1.5 and 2.5 h at approximately 300 and
700 ng/ml for the 10 mg and 20 mg dose level, respectively.
These levels correspond with 0.6–1.35 μM AT-101.
Discussion
Despite significant improvements in the treatment of
patients with inoperable head and neck cancer, recur-
rence rates remain unacceptably high. Thus, there is
a clear need to develop new therapeutic approaches
to further enhance the anti-tumor efficacy of existing
standard regimens, such as cisplatin-based chemora-
diotherapy. Overexpression of anti-apoptotic members
of the Bcl-2 family is frequently observed in HNSCC
and has been associated with resistance to radio- and
chemotherapy and with poor prognosis [4–8]. There-
fore, in the present studies we focused on AT-101, a
BH3 mimetic and small molecule inhibitor of pro-
survival Bcl-2 proteins, and its potential to increase
the cytotoxic effect of radiation in HNSCC in vitro.
Our results show that AT-101, only when added after
radiation, enhances apoptosis to synergistic levels, and
acts as a radiosensitizer in clonogenic survival assays.
To address the question whether the effective in vitro
concentrations of AT-101 correspond with those
achievable in a clinical setting, we determined AT-101
plasma levels in a subset of patients included in our
Fig. 1 Expression of Bcl-xL, Bcl-2, and Mcl-1 in HNSCC. Western blot
analysis demonstrating the expression of the anti-apoptotic proteins
Bcl-xL, Bcl-2, and Mcl-1 in four different head and neck cancer cell
lines, UM-SCC-11B, UM-SCC-14C, UM-SCC-22A and VU-SCC-OE
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phase I/II trial. Indeed, plasma levels of AT-101 were
comparable with the low micromolar radiosensitizing
concentrations in vitro.
A synthetic class of BH3 mimetics that has been devel-
oped recently shows interesting results regarding their
capacity to radiosensitize cancer cells, including ABT-
737, a molecule with high affinity for Bcl-2 and Bcl-xL,
and its analogue the clinically more favorable, ABT-263.
These compounds do not or only weakly target Mcl-1
[28, 29], whereas AT-101 demonstrates a more favorable
binding profile towards Mcl-1 [30]. Studies with ABT-
737 and ABT-263 now suggest that Mcl-1 plays a role in
resistance to these compounds [28, 31]. A recent study
on radiation and BH3 mimetics in breast cancer showed
treatment with ABT-737 alone elevated Mcl-1. ABT-737
together with radiation, however, demonstrated a syner-
gistic effect on breast cancer cells by downregulation of
Mcl-1 [32]. Also a study on pancreatic cancer cells eval-
uated Mcl-1 as a target for radiosensitization [33]. These
studies suggest that ABT-737 or ABT-263 may be sub-
optimal to target Mcl-1, in particular in combination
with radiation.
AT-101, the cis- or (-)-enantiomer of racemic Gossy-
pol, is a naturally occurring polyphenolic dialdehyde de-
rived from cottonseed. Gossypol enantiomers, including
AT-101, have been used as cytotoxic agents in vitro and
in vivo using different tumor cell lines from both solid
[13–15, 34, 35] and leukemic origin [16]. Importantly,
only minimal effects were observed on normal cells
[13, 14], indicating a certain degree of tumor selectiv-
ity. Several groups have investigated the combined ef-
fects of AT-101 and chemo- or radiotherapy [17, 18, 36].
In human prostate cancer cells, AT-101 potently enhanced
radiation-induced apoptosis and growth inhibition and re-
duced clonogenic survival [18]. We showed in two
human leukemic cell lines an additive to synergistic
interaction between radiation and AT-101 [16]. Inter-
estingly, HNSCC cell lines made resistant to cisplatin
retained their apoptosis sensitivity towards AT-101
[13, 34]. In vivo, the anti-tumor effect of AT-101 has
been tested as single agent [37] and in combination with
radiation [18] and chemotherapy [38]. In an orthotopic
xenograft model of HNSCC with high Bcl-xL expression,
daily i.p. injection of AT-101 resulted in a significant
tumor growth delay as compared to control animals [37].
Histopathological analysis showed a decrease in mitotic
index and an increase in apoptosis in the AT-101-treated
tumors. Treatment was well tolerated, as reversible mod-
erate weight loss was the only observed side effect. In a
prostate cancer xenograft model daily oral AT-101 was
UM-SSC-11B UM-SSC-11B






























































































Fig. 2 Dose- and time-dependent induction of apoptosis by radiation (a,c) and AT-101 (b,d) in HNSCC cell lines UM-SCC-11B (a,b) and
VU-SCC-OE (c,d). Apoptosis was quantified 72 h after radiation and 48 h after exposure to AT-101. Data represent mean values ± SEM of
an average of 11 independent experiments, performed in duplicate. Inserts show the time-dependency of radiation- and AT-101-induced
apoptosis at the indicated doses
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compared with fractionated radiotherapy and with the
combination of both [18]. Especially when larger tu-
mors were treated, only the combination of AT-101
and radiation achieved significant anti-tumor activity.
Tumor tissue specimens showed not only a significant
increase in apoptosis after combined treatment, but
also a strong inhibition of tumor angiogenesis. No signifi-
cant weight loss or obvious organ toxicities were observed.
From these experimental studies it can be concluded that
AT-101 has significant anti-cancer activity as single agent,
but is much more effective in combination with other
cytotoxic regimens like cisplatin and radiation therapy.
Upon oral administration, it has demonstrated little toxic
side effects in animals.
Clinical studies on AT-101 as single agent or com-
bined with chemotherapy are limited, but indicate good
tolerability [19–23]. Clinical experience with AT-101 in
combination with (chemo-)radiotherapy is even sparser
Fig. 4 Sequence-dependent interaction between radiation and
AT-101. Radiation and AT-101 were applied either concurrently or
sequentially at the indicated doses. In the sequential schedule, AT-101
was administered either 24 h before radiation or 24 h after radiation.
a: UM-SCC-11B; b: VU-SCC-OE. Data presented are representative of at
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Fig. 5 Effect of AT-101 on clonogenic survival after radiation. Clonogenic
survival curves of VU-SCC-OE cells after radiation in the absence
(solid line) or presence of 1 μM AT-101 (normalized dashed line)
are shown. Graphs show representative curves of at least 3 experiments
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Fig. 3 Synergistic interaction between radiation and AT-101. Figure 3a
and b illustrate apoptosis induction in two HNSCC lines after radiation,
AT-101 and their combination at the indicated doses. For the
combination experiments, AT-101 was administered 24 h after radiation.
These graphs represent the results of at least 3 independent experiments
performed in duplo. Figure 3c shows an isobolographic analysis of the
combined effect of 29 % apoptosis induced by 10 Gy radiation and
15 μM AT-101. The same level of apoptosis can be induced by 18.4 Gy
of radiation or 44 μM of AT-101, respectively. The combination point (▲)
below the envelope of additivity indicates a synergistic interaction
between both stimuli. Note that in all conditions shown, the CI that
refers to the combination index, is smaller than 1.0, indicating synergy as well
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[39], but accumulating from several ongoing or recently
completed phase I studies, including ours in HNSCC.
In the present studies, we demonstrate a dose- and
time-dependent increase in apoptosis by radiation and
AT-101 in two human HNSCC cell lines expressing the
pro-survival Bcl-2 family members Bcl-xL, Bcl-2, and
Mcl-1, all established targets of AT-101. By performing
isobolographic analysis and calculating the Combination
Indices, we characterized the type of interaction between
both treatments as synergistic. These findings are in
agreement with the results from studies using other cell
systems [16, 18]. We also found that this synergistic
interaction between radiation and AT-101 was only
present when AT-101 was added after radiation, as ob-
served in other cell systems as well [16, 18]. This appar-
ent sequence-dependency is poorly understood and
thought to be cell cycle related [18]. In a previous study
[16], we provided evidence that activation of the SAPK/
JNK signal transduction pathway plays a significant role
in AT-101-induced apoptosis. Because radiation is a
well-known activator of SAPK/JNK [40] and it has been
shown that SAPK/JNK translocates to the mitochondria
upon irradiation where it phosphorylates and inactivates
Bcl-xL, Bcl-2 and Mcl-1 [41–43], this mechanism may pro-
vide an alternative explanation for the observed sequence-
dependency.
It has been shown that genetic or pharmacological
modulation of radiation-induced apoptosis frequently
also impacts on radiosensitivity [44, 45]. Therefore, we
evaluated the effect of AT-101 on clonogenic survival
after irradiation. Indeed, at concentrations that do not
induce significant levels of apoptosis, a clear radiosensi-
tizing effect was observed. This radiosensitizing potential
of AT-101 most likely depends on the cell type studied,
as it has been demonstrated in certain cell systems
[17, 36], but not in others [16]. In a number of differ-
ent tumor cell lines, including HNSCC, radiosensitization
by AT-101 was found to result from reduced double-
strand break repair [46]. Others have suggested that in-
creased autophagic cell death plays an important role in
AT-101-induced inhibition of clonogenic survival of irra-
diated glioblastoma cells [36].
To determine whether the radiosensitizing concentra-
tions of AT-101 are comparable with the plasma levels
that can be achieved in patients, we analyzed the phar-
macokinetic data collected in our clinical phase I/II
study. At daily doses of 10–20 mg, plasma levels peaked
around 2 h after intake, suggesting slow absorption.
Maximum plasma concentrations were in the micromo-
lar range, corresponding to those that induced radiosen-
sitization in vitro. Both the maximum observed plasma
concentration and the time to reach this value are simi-
lar to other reports [37]. Although it is difficult to com-
pare in vitro with in vivo drug concentrations, it is
reassuring that no major differences were found. Regard-
ing the scheduling of radiotherapy and AT-101, daily ra-
diation was given just prior to or at maximal plasma
concentrations. Evidently, more clinical studies are
needed to define safety and efficacy of AT-101 in com-
bination with radiation, and to determine intra-tumoral
drug concentrations for optimal scheduling.
Conclusions
In summary, we showed that AT-101 synergistically en-
hanced radiation-induced apoptosis in HNSCC in vitro
in a sequence-dependent manner. In addition, in vitro
radiosensitization was observed at clinically achievable
plasma levels. These findings provide a rationale to fur-
ther evaluate AT-101 in combination with standard
(chemo-)radiation in Bcl-2-overexpressing tumors, such
as head and neck squamous cell carcinoma.
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Fig. 6 Clinical pharmacokinetics of AT-101. AT-101 concentration was
measured by HPLC in patient plasma samples collected at 30 min, 1, 2,
3, 4, 5, 6, 7, 8 and 24 h after oral intake of AT-101. Pharmacokinetic
profiles are shown for the AT-101 dose levels of 10 mg (n = 13) and
20 mg (n = 1). Data represent mean values ± SD
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